Business Wire

The LYCRA Company and HeiQ Introduce New LYCRA® naturalFX™ Technology That Offers Durable Comfort Stretch and Fit for 100% Cotton Knitwear

Share

The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, today announced the launch of LYCRA® naturalFX™ technology, a proprietary textile finishing process for 100% cotton knit garments designed for mass market applications. Developed in collaboration with HeiQ, an industry leader in performance finish technologies, this application is the latest example of both companies’ ongoing efforts to bring more innovative and sustainable textile technologies to consumers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005095/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The LYCRA Company and HeiQ introduce new LYCRA® naturalFX™ technology that offers durable comfort stretch and fit for 100% cotton knitwear. (Photo: Business Wire)

LYCRA® naturalFX™ technology, powered by HeiQ, enhances cotton knitwear, addressing critical consumer pain points, and improving the consumer’s overall wearing experience. This technology provides durable comfort stretch, fit, and soft hand-feel to 100% cotton knitwear compared to conventional finishes.

Even after repeated washing and wearing, LYCRA® naturalFX™ technology helps knitwear retain its shape, which helps extend the garment’s lifespan and potentially reduce its environmental impact.

“LYCRA® naturalFX™ technology enhances the stretch and recovery properties of cotton knit fabrics and does so in a durable way with outstandingly soft hand,” said Nicolas Banyols, chief commercial officer at The LYCRA Company. “This breakthrough innovation not only improves the performance of everyday 100% cotton knitwear but is easy for mills to implement as it requires no investment in new equipment. We value HeiQ’s technical expertise and are excited to collaborate on the commercialization of this technology.”

All knits that use LYCRA® naturalFX™ technology can be submitted to The LYCRA Company’s labs for quality control testing to ensure all consumer benefits are delivered, including comfort stretch, breathability, and durable fit. New logos will feature both the LYCRA® and HeiQ brands and will be supported by customizable co-branded POS materials featuring the tagline, “In Sync with Nature’s Rhythm,” which are also available to brands and retailers.

While The LYCRA Company is leading the commercialization of this technology, HeiQ will collaborate and support the introduction through their brand network as well as manufacturing and selling the finishing directly to textile mills, leveraging their established global technical services to deliver optimized performance.

“Combining The LYCRA Company’s expertise in stretch fibers with HeiQ’s renowned innovation in textile chemical finishing has resulted in a truly unique, added-value technology that offers enhanced performance to cotton knitwear,” added Mike Mordente, head of the business unit textiles at HeiQ. “I am confident that LYCRA® naturalFX™ technology will open up a new generation of enhanced stretch and recovery garments with comfort and durability.”

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.

LYCRA® is a trademark of The LYCRA Company.

About HeiQ

Founded in 2005 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH) and listed on the London Stock Exchange Main Market (LSE:HEIQ), HeiQ is a leader in textile and materials innovation creating some of the most effective, durable and high-performance technologies on the market today. HeiQ strives to improve the lives of billions of people through pioneering textiles and materials innovation. Combining three areas of expertise – scientific research, specialty materials manufacturing and consumer ingredient branding – HeiQ is the ideal innovation partner to create differentiating and sustainable products and capture the added value at the point of sale. With its 14 offices, 7 manufacturing sites and 7 R&D hubs, HeiQ today employs 240 professionals. It has a total capacity of 45,000 tons of specialty chemicals per year and serves over 1,000 industrial customers in over 60 countries. Today, HeiQ’s consumer goods and medical devices can be found in 56 countries. For more information, visit www.heiq.com.

HeiQ is a trademark or registered trademark of HeiQ Materials AG.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Karie J. Ford
Karie.J.Ford@Lycra.com

Jorge Fiens
jorge.fiens@heiq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye